Company intelligence / Profile preview

SOLA Biosciences

Boston/Natick, Massachusetts, United Statessola-bio.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

SOLA's lead candidate SOL-257 has shown promising preclinical results in ALS models, demonstrating potential to delay disease progression and prolong lifespan in ALS model animals[1][4]. The company presented preclinical proof-of-concept data for SOL-257 at Neuroscience 2023 and ALS One Symposium[4].

Therapeutic areas: Neurology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

8 assets

SOL-257

Preclinical

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on SOLA Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOLA Biosciences.

Explore the full profile